These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1421051)

  • 1. Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1.
    Smithers JA; Thompson GA; Kenny MT; Dulworth JK; Kulmala HK; Lewis EW; Ruberg SJ; Shapiro BE; Keane WF; Halstenson CE
    Biopharm Drug Dispos; 1992 Nov; 13(8):571-81. PubMed ID: 1421051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers.
    Thompson GA; Smithers JA; Kenny MT; Dulworth JK; Kulmala HK; Yuh L; Lewis EW; Antony KK
    Biopharm Drug Dispos; 1992 Apr; 13(3):213-20. PubMed ID: 1533542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.
    Smithers JA; Kulmala HK; Thompson GA; Antony KK; Lewis EW; Ruberg SJ; Kenny MT; Dulworth JK; Brackman MA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):115-20. PubMed ID: 1534211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of teicoplanin.
    Wilson AP
    Clin Pharmacokinet; 2000 Sep; 39(3):167-83. PubMed ID: 11020133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of teicoplanin in varying degrees of renal function.
    Lam YW; Kapusnik-Uner JE; Sachdeva M; Hackbarth C; Gambertoglio JG; Sande MA
    Clin Pharmacol Ther; 1990 May; 47(5):655-61. PubMed ID: 2140543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.
    Agersø H; Seiding Larsen L; Riis A; Lövgren U; Karlsson MO; Senderovitz T
    Br J Clin Pharmacol; 2004 Oct; 58(4):352-8. PubMed ID: 15373927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teicoplanin pharmacokinetics in patients with chronic renal failure.
    Bonati M; Traina GL; Villa G; Salvadeo A; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
    Clin Pharmacokinet; 1987 Apr; 12(4):292-301. PubMed ID: 2954735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.
    Domart Y; Pierre C; Clair B; Garaud JJ; Regnier B; Gibert C
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1600-4. PubMed ID: 2963586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
    Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
    Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.
    Del Favero A; Patoia L; Rosina R; Buniva G; Danese A; Bernareggi A; Molini E; Cavenaghi L
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2551-7. PubMed ID: 1839759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans.
    Antony KK; Lewis EW; Kenny MT; Dulworth JK; Brackman MB; Kuzma R; Yuh L; Eller MG; Thompson GA
    J Pharm Sci; 1991 Jun; 80(6):605-7. PubMed ID: 1834827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
    Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis.
    Papaioannou MG; Marinaki S; Pappas M; Stamatiadis D; Giamarellos-Bourboulis EJ; Giamarellou H; Stathakis C
    Int J Antimicrob Agents; 2002 Mar; 19(3):233-6. PubMed ID: 11932147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.